Jack Shuang Hou: CorTec Wins FDA TAP Entry for Brain Interchange
Jack Shuang Hou, Scientific Director at Jtests and CorDx, shared on LinkedIn:
”CorTec Wins FDA TAP Entry for Brain Interchange – Frank Desiere Highlights Third Stroke Rehab Implant as BCI Program Gains Regulatory Momentum
A meaningful neurotech milestone: CorTec has now secured both FDA Breakthrough Device Designation and acceptance into the FDA Total Product Life Cycle Advisory Program (TAP) for Brain Interchange in stroke motor rehabilitation, while advancing its NIH-funded clinical study with a third patient implanted at Harborview Medical Center.
Key leaders
- Frank Desiere – PhD MBA — Chief Executive Officer, CorTec
- Jeff Ojemann, MD — Vice Chair and Professor of Neurological Surgery, University of Washington – School of Medicine
- Martin Schuettler — Chief Technology Officer and Co-Founder, CorTec
- Mara Assis – Head of Regulatory Affairs and Quality Management, CorTec
FDA validation goes beyond breakthrough status
- Brain Interchange accepted into FDA TAP, a limited program for priority breakthrough technologies
- TAP adds structured FDA support on study design, regulatory strategy, and early payer engagement including CMS
- This follows CorTec’s recent Breakthrough Device Designation for stroke rehabilitation.
Strategic impact:
This is not just a regulatory badge – it strengthens the path from clinical evidence – approval – reimbursement.
Clinical execution is advancing in parallel
- Third patient implanted at Harborview Medical Center in Seattle
- Trial is NIH-funded, FDA-authorized, and conducted by researchers from University of Washington and UCLA
- First participant has now shown nine months of stable wireless sensing and cortical stimulation performance.
Signal:
CorTec is building both regulatory momentum and real human durability data at the same time.
A European neurotech platform gaining global relevance
- Brain Interchange is a fully implantable, wireless, bidirectional closed-loop BCI
- CorTec says it is the only European company with such a platform in FDA-authorized U.S. clinical evaluation
- The platform is also being explored in epilepsy, depression, and communication restoration.
My takeaway
This is a strong example of how next-generation neurotech wins:
- differentiated platform
- durable implant performance
- smart regulatory sequencing
- early reimbursement thinking
Bottom line
CorTec is moving Brain Interchange from promising BCI concept toward a real therapeutic platform for stroke recovery, and FDA TAP entry materially increases the credibility of that path.”
Stay updated with Hemostasis Today.
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA
-
May 5, 2026, 15:28Soumen Bhattacharyya: Hyperhomocysteinemia and Thrombosis – What Clinicians Should Know
-
May 5, 2026, 15:06Wolfgang Miesbach: How Should We Approach GI Angiodysplasia in VWD?
-
May 5, 2026, 14:48What Constitutes High Risk for Venous Thromboembolism? – JTH
-
May 5, 2026, 14:41How Real-Time Data, Rehabilitation Registries, and Patient-Reported Outcomes Can Transform Practice – European Stroke Organisation
-
May 5, 2026, 14:41Driving National Change for Bleeding Disorders – WFH